Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and Cytokines in Macular Edema with RVO
NCT02169648Unknown
- Sponsor
- Tokyo Medical University
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in macular edema, sponsored by Tokyo Medical University. Primary endpoint: Visual function by ranibizumab in macular edema with retinal vein occlusion at 1 year. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT02169648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169648.